Department of Medicine, New York Medical College, Valhalla.
Am J Med. 2013 Nov;126(11):1016.e1-7. doi: 10.1016/j.amjmed.2013.03.021. Epub 2013 Aug 29.
Despite the widespread availability of plasmapheresis as a therapy, thrombotic thrombocytopenic purpura is associated with significant morbidity and mortality. There is a paucity of data on the predictors of poor clinical outcome in this population. Acute myocardial infarction is a recognized complication of thrombotic thrombocytopenic purpura. Little is known about the magnitude of this problem, its risk factors, and its influence on mortality in patients hospitalized with thrombotic thrombocytopenic purpura.
We used the 2001-2010 Nationwide Inpatient Sample database to identify patients aged ≥18 years with the diagnosis of thrombotic thrombocytopenic purpura (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 446.6) who also received therapeutic plasmapheresis (ICD-9-CM code 99.71) during the hospitalization. Patients with acute myocardial infarction were identified using the Healthcare Cost and Utilization Project Clinical Classification Software code 100. Stepwise logistic regression was used to determine independent predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura patients.
Among the 4032 patients (mean age 47.5 years, 67.7% women, and 36.9% white) with thrombotic thrombocytopenic purpura who also underwent plasmapheresis, in-hospital mortality was 11.1%. Independent predictors of increased in-hospital mortality were older age (odds ratio [OR] 1.03; 95% confidence interval [CI], 1.02-1.04; P <.001), acute myocardial infarction (OR 1.89; 95% CI, 1.24-2.88; P = .003), acute renal failure (OR 2.75; 95% CI, 2.11-3.58; P <.001), congestive heart failure (OR 1.66; 95% CI, 1.17-2.34; P = .004), acute cerebrovascular disease (OR 2.68; 95% CI, 1.87-3.85; P <.001), cancer (OR 2.49; 95% CI, 1.83-3.40; P <.001), and sepsis (OR 2.59; 95% CI, 1.88-3.59; P <.001). Independent predictors of acute myocardial infarction were older age (OR 1.03; 95% CI, 1.02-1.04; P <.001), smoking (OR 1.60; 95% CI, 1.14-2.24; P = .007), known coronary artery disease (OR 2.59; 95% CI, 1.76-3.81; P <.001), and congestive heart failure (OR 2.40; 95% CI, 1.71-3.37; P <.001).
In this large national database, patients with thrombotic thrombocytopenic purpura had an in-hospital mortality rate of 11.1% and an acute myocardial infarction rate of 5.7%. Predictors of in-hospital mortality were older age, acute myocardial infarction, acute renal failure, congestive heart failure, acute cerebrovascular disease, cancer, and sepsis. Predictors of acute myocardial infarction were older age, smoking, known coronary artery disease, and congestive heart failure.
尽管血浆置换作为一种治疗方法广泛应用,但血栓性血小板减少性紫癜仍与较高的发病率和死亡率相关。关于该人群不良临床结局的预测因素的数据很少。急性心肌梗死是血栓性血小板减少性紫癜的一种公认并发症。对于患有血栓性血小板减少性紫癜的住院患者中,急性心肌梗死的发生率、危险因素及其对死亡率的影响,人们知之甚少。
我们使用 2001-2010 年全国住院患者样本数据库,确定年龄≥18 岁且诊断为血栓性血小板减少性紫癜(国际疾病分类,第 9 版,临床修订版[ICD-9-CM 代码 446.6])的患者,并在住院期间接受治疗性血浆置换(ICD-9-CM 代码 99.71)。使用医疗保健成本和利用项目临床分类软件代码 100 识别急性心肌梗死患者。逐步逻辑回归用于确定血栓性血小板减少性紫癜患者住院期间死亡和急性心肌梗死的独立预测因素。
在 4032 例(平均年龄 47.5 岁,67.7%为女性,36.9%为白人)接受血栓性血小板减少性紫癜治疗且同时接受血浆置换的患者中,住院死亡率为 11.1%。住院死亡率增加的独立预测因素为年龄较大(比值比[OR]1.03;95%置信区间[CI],1.02-1.04;P<.001)、急性心肌梗死(OR 1.89;95%CI,1.24-2.88;P=0.003)、急性肾衰竭(OR 2.75;95%CI,2.11-3.58;P<.001)、充血性心力衰竭(OR 1.66;95%CI,1.17-2.34;P=0.004)、急性脑血管病(OR 2.68;95%CI,1.87-3.85;P<.001)、癌症(OR 2.49;95%CI,1.83-3.40;P<.001)和脓毒症(OR 2.59;95%CI,1.88-3.59;P<.001)。急性心肌梗死的独立预测因素为年龄较大(OR 1.03;95%CI,1.02-1.04;P<.001)、吸烟(OR 1.60;95%CI,1.14-2.24;P=0.007)、已知冠心病(OR 2.59;95%CI,1.76-3.81;P<.001)和充血性心力衰竭(OR 2.40;95%CI,1.71-3.37;P<.001)。
在这个大型全国数据库中,血栓性血小板减少性紫癜患者的住院死亡率为 11.1%,急性心肌梗死发生率为 5.7%。住院死亡率的预测因素为年龄较大、急性心肌梗死、急性肾衰竭、充血性心力衰竭、急性脑血管病、癌症和脓毒症。急性心肌梗死的预测因素为年龄较大、吸烟、已知冠心病和充血性心力衰竭。